Gam Holding Ag Bei Gene, Ltd. Transaction History

Gam Holding Ag

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 13, 2018	SELL	$152.62 - $189.66 $2.37 Million - $2.94 Million	-15,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$97.41 - $177.22 $438,345 - $797,490	4,500 Added 40.91%	15,500 $2.6 Million
Q4 2017 Feb 14, 2018	BUY	$79.6 - $114.73 $875,599 - $1.26 Million	11,000	11,000 $1.08 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Gam Holding Ag, based on Form 13F filings with the SEC.

Stay updated on Gam Holding Ag with notifications on news.